Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K dated September 8, 2025. The filing reports on a corporate event occurring on the same date, specifically the presentation of clinical data at the American Society of Bone and Mineral Research 2025 Annual Meeting.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the presentation of additional clinical data from the Company's Phase 1 clinical trial of KER-065 in healthy male volunteers. This data was presented on September 6, 2025, and the associated press release is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard incorporation of the press release. The document serves solely to disclose the clinical data presentation event.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated September 8, 2025) for the specific clinical data results regarding KER-065.
- Verify the safety and pharmacokinetic outcomes of the Phase 1 trial in healthy male volunteers.
- Check subsequent filings for any updates on the development timeline or next steps for the KER-065 program.